Recently, a collaborative EORTC-GIMEMA trial has demonstrated a better response rate and survival with high dose Ara-C in very high risk setting patients, including AML FLT3-ITD cases [22], that presumably would show high hENT1 expression according to our results. This evidence concerns the gene FLT3 and acute myeloid leukemia.